drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An intravenous anti-CD38 IgG1 monoclonal antibody that binds CD38 on plasma cells and plasmablasts and depletes them via Fc-mediated cytotoxicity/phagocytosis and complement, reducing pathogenic autoantibody production; also known as HIB202, BIIB148, MOR202, and TJ202.
nci_thesaurus_concept_id
C97954
nci_thesaurus_definition
A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Felzartamab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
felzartamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fully human IgG1 anti-CD38 monoclonal antibody that binds CD38 on plasma cells/plasmablasts (and other CD38+ cells) and depletes them via Fc-mediated effector functions (ADCC/ADCP) and complement-dependent cytotoxicity, thereby reducing pathogenic autoantibody production; in oncology, induces lysis of CD38-expressing tumor cells.
drug_name
Felzartamab
nct_id_drug_ref
NCT06064929